{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:30:30Z","timestamp":1789734630583,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Spanish Cell Therapy Network","award":["RD16\/0011\/0028"],"award-info":[{"award-number":["RD16\/0011\/0028"]}]},{"name":"Generalitat de Catalunya as Consolidated Research Groups","award":["2017SGR719"],"award-info":[{"award-number":["2017SGR719"]}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jcyt.2018.09.009","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T11:41:22Z","timestamp":1542282082000},"page":"32-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Levels of IL-17F and IL-33 correlate with HLA-DR activation in clinical-grade human bone marrow\u2013derived multipotent mesenchymal stromal cell expansion cultures"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0039-7779","authenticated-orcid":false,"given":"MARTA","family":"GRAU-VORSTER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LUCIANO","family":"RODR\u00cdGUEZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00cdLVIA","family":"TORRENTS-ZAPATA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANIEL","family":"VIVAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARGARITA","family":"CODINACH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARGARITA","family":"BLANCO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IRENE","family":"OLIVER-VILA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOAN","family":"GARC\u00cdA-L\u00d3PEZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9719-5235","authenticated-orcid":false,"given":"JOAQUIM","family":"VIVES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jcyt.2018.09.009_bib0001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/157488812799219027","article-title":"Sources of adult mesenchymal stem cells and their applicability for musculoskeletal applications","volume":"7","author":"Mohal","year":"2012","journal-title":"Curr Stem Cell Res Ther"},{"key":"10.1016\/j.jcyt.2018.09.009_bib0002","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1038\/emm.2013.94","article-title":"Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine","volume":"45","author":"Murphy","year":"2013","journal-title":"Exp Mol Med"},{"issue":"9","key":"10.1016\/j.jcyt.2018.09.009_bib0003","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.medcli.2016.11.033","article-title":"Characteristics, applications and prospects of mesenchymal stem cells in cell therapy","volume":"148","author":"Guadix","year":"2017","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.jcyt.2018.09.009_bib0004","series-title":"Reference Module in Biomedical Sciences","article-title":"Multipotent mesenchymal stromal cells from bone marrow for current and potential clinical applications","author":"Vives","year":"2018"},{"issue":"6","key":"10.1016\/j.jcyt.2018.09.009_bib0005","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2018.09.009_bib0006","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells","volume":"8","author":"Dominici","year":"2006","journal-title":"Int Soc Cell Ther position statement Cytotherapy"},{"issue":"2","key":"10.1016\/j.jcyt.2018.09.009_bib0007","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.stem.2014.01.013","article-title":"MSC-based product characterization for clinical trials: an FDA perspective","volume":"14","author":"Mendicino","year":"2014","journal-title":"Cell Stem Cell"},{"issue":"9","key":"10.1016\/j.jcyt.2018.09.009_bib0008","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jcyt.2016.05.012","article-title":"Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow-derived multipotent mesenchymal stromal cells","volume":"18","author":"Codinach","year":"2016","journal-title":"Cytotherapy"},{"issue":"10","key":"10.1016\/j.jcyt.2018.09.009_bib0009","doi-asserted-by":"crossref","first-page":"e47559","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials","volume":"7","author":"Lalu","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jcyt.2018.09.009_bib0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s13577-014-0095-x","article-title":"Mesenchymal stem cell therapy and acute graft-versus-host disease: a review","volume":"27","author":"Amorin","year":"2014","journal-title":"Hum Cell"},{"issue":"416","key":"10.1016\/j.jcyt.2018.09.009_bib0011","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7828","article-title":"Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation","volume":"9","author":"Galleu","year":"2017","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.jcyt.2018.09.009_bib0012","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1002\/term.2254","article-title":"A reproducible method for the isolation and expansion of ovine mesenchymal stromal cells from bone marrow for use in regenerative medicine preclinical studies","volume":"11","author":"Caminal","year":"2017","journal-title":"J Tissue Eng Regen Med"},{"key":"10.1016\/j.jcyt.2018.09.009_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/cpsc.43","article-title":"Derivation of Multipotent Mesenchymal Stromal Cells from Ovine Bone Marrow","volume":"44","author":"Vivas","year":"2018","journal-title":"Curr Protoc Stem Cell Biol"},{"issue":"1","key":"10.1016\/j.jcyt.2018.09.009_bib0014","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10616-017-0186-0","article-title":"Optimisation of a potency assay for the assessment of immunomodulative potential of clinical grade multipotent mesenchymal stromal cells","volume":"70","author":"Oliver-Vila","year":"2018","journal-title":"Cytotechnology"},{"issue":"3","key":"10.1016\/j.jcyt.2018.09.009_bib0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrd3052","article-title":"Challenges with advanced therapy medicinal products and how to meet them","volume":"9","author":"CAT","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcyt.2018.09.009_bib0016","doi-asserted-by":"crossref","DOI":"10.1089\/ten.tea.2013.0589","article-title":"White Paper on How to Go Forward with Cell-Based Advanced Therapies in Europe","author":"Erben","year":"2014","journal-title":"Tissue Eng Part A"},{"issue":"1","key":"10.1016\/j.jcyt.2018.09.009_bib0017","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12967-016-0892-y","article-title":"Clinical-scale expansion of mesenchymal stromal cells: a large banking experience","volume":"14","author":"Lechanteur","year":"2016","journal-title":"J Transl Med"},{"issue":"6","key":"10.1016\/j.jcyt.2018.09.009_bib0018","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1089\/scd.2014.0299","article-title":"Ex vivo expanded mesenchymal stromal cell minimal quality requirements for clinical application","volume":"24","author":"Torre","year":"2015","journal-title":"Stem Cells Dev"},{"issue":"8","key":"10.1016\/j.jcyt.2018.09.009_bib0019","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood-2009-05-219907","article-title":"Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation","volume":"115","author":"Tarte","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jcyt.2018.09.009_bib0020","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.imlet.2015.06.006","article-title":"Clinical grade expansion of MSCs","volume":"168","author":"Capelli","year":"2015","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jcyt.2018.09.009_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.knee.2015.08.013","article-title":"Final results of a phase I-II trial using ex vivo expanded autologous Mesenchymal Stromal Cells for the treatment of osteoarthritis of the knee confirming safety and suggesting cartilage regeneration","volume":"23","author":"Soler","year":"2016","journal-title":"Knee"},{"issue":"1","key":"10.1016\/j.jcyt.2018.09.009_bib0022","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1002\/term.2323","article-title":"Clinical translation of a mesenchymal stromal cell-based therapy developed in a large animal model and two case studies of the treatment of atrophic pseudoarthrosis","volume":"12","author":"Prat","year":"2018","journal-title":"Journal of Tissue Engineering and Regenerative Medicine"},{"issue":"Suppl 9","key":"10.1016\/j.jcyt.2018.09.009_bib0023","article-title":"Development of an advanced cell therapy product indicated for the treatment of gonarthrosis","volume":"9","author":"Vives","year":"2015","journal-title":"BMC Proceedings"},{"issue":"3","key":"10.1016\/j.jcyt.2018.09.009_bib0024","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.cyto.2012.03.013","article-title":"The relationship of cytomegalovirus (CMV) infection with circulatory IFN-alpha levels and IL-7 receptor alpha expression on CD8+ T cells in human aging","volume":"58","author":"Lee","year":"2012","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.jcyt.2018.09.009_bib0025","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00134-015-4077-6","article-title":"Interferon-gamma production by CMV-specific CD8+ T lymphocytes provides protection against cytomegalovirus reactivation in critically ill patients","volume":"42","author":"Caston","year":"2016","journal-title":"Intensive Care Med"},{"issue":"12","key":"10.1016\/j.jcyt.2018.09.009_bib0026","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/art.27736","article-title":"Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells","volume":"62","author":"Bocelli-Tyndall","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.jcyt.2018.09.009_bib0027","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0301-472X(03)00110-3","article-title":"HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells","volume":"31","author":"Le Blanc","year":"2003","journal-title":"Exp Hematol"},{"issue":"11","key":"10.1016\/j.jcyt.2018.09.009_bib0028","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2018.09.009_bib0029","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cyto.2008.12.024","article-title":"IL-17F: regulation, signaling and function in inflammation","volume":"46","author":"Chang","year":"2009","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.jcyt.2018.09.009_bib0030","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/cei.12396","article-title":"Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection","volume":"178","author":"Jenabian","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.jcyt.2018.09.009_bib0031","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23 as a drug target for autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.jcyt.2018.09.009_bib0032","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/scrt217","article-title":"Production of mesenchymal stromal\/stem cells according to good manufacturing practices: a review","volume":"4","author":"Sensebe","year":"2013","journal-title":"Stem Cell Res Ther"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324918306182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324918306182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:37:21Z","timestamp":1761442641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324918306182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1465324918306182"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2018.09.009","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Levels of IL-17F and IL-33 correlate with HLA-DR activation in clinical-grade human bone marrow\u2013derived multipotent mesenchymal stromal cell expansion cultures","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2018.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}